Skip to main content

FDA Approves Tapentadol ER for Diabetic Neuropathy


August 29, 2012 — The US Food and Drug Administration (FDA) has approved tapentadol extended-release (ER) (Nucynta, Janssen Pharmaceuticals, Inc) for the management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults for whom a continuous opioid analgesic is required over an extended time.
It is the first opioid to receive this indication, the company notes in a statement today.
DPN, the most common type of neuropathy, affects an estimated 16% of the more than 25 million Americans who have diabetes. The condition is often unreported and untreated, with an estimated 2 out of 5 cases not receiving care.
Tapentadol ER is already approved for the treatment of moderate to severe chronic pain in adults requiring a continuous opioid analgesic for an extended period. It is a centrally acting synthetic analgesic, although the exact mechanism of action is unknown, the release states.
"Although the clinical relevance is unclear," the company notes, preclinical studies showed that it acts as both a mu-opioid receptor and a norepinephrine reuptake inhibitor.
Better Pain Control
The supplemental New Drug Application for this indication was based on data from 2 randomly assigned withdrawal, placebo-controlled phase 3 trials showing that among patients who had at least a 1-point reduction in pain intensity during 3 weeks of treatment with tapentadol ER, those who continued on the same dose titrated to balance individual tolerability and efficacy (100 to 250 mg twice daily) for an additional 12 weeks experienced significantly better pain control compared with those who switched to placebo.
The research also demonstrated that tapentadol ER was generally well tolerated. The most common adverse reactions, affecting 10% or more of treated patients, were nausea, constipation, vomiting, dizziness, headache, and somnolence.
Approval of the drug for this indication "represents the ongoing commitment of Janssen to bring new and innovative products to patients and physicians for the management of pain," comments Paul Chang, vice president of medical affairs at Janssen Pharmaceuticals, Inc, in the press release.
Currently, 2 drugs (duloxetine, a selective serotonin and norepinephrine reuptake inhibitor, and pregabalin, an anticonvulsant) are approved in the United States for the management of pain associated with DPN.
However, alternative treatments are needed, according to the press statement. Because the complex pathophysiology of DPN involves both central and peripheral nervous mechanisms, some patients with DPN may require treatment with multiple agents, it notes.
Evidence-Based Guidelines
Evidence-based guidelines on the treatment of painful diabetic neuropathy, released last year at the 63rd Annual Meeting of the American Academy of Neurology in Honolulu, Hawaii, and published in Neurology, noted that some opioids, including dextromethorphan, morphine sulfate, tramadol, and oxycodone, met criteria for "Moderate Evidence, Level B" endorsement.
The guideline authors noted that the use of opioids for chronic nonmalignant pain has "gained credence over the last decade" because of the studies reviewed in their document. However, both tramadol and dextromethorphan are associated with substantial adverse events, including sedation with both agents, and nausea and constipation with tramadol. Use of these agents can also be associated with the development of novel pain syndromes, such as rebound headache, the authors note, and long-term use can lead to tolerance and frequent escalation of dose.
Also receiving "Moderate Evidence, Level B" endorsement from the guideline authors were the anticonvulsant drugs gabapentin and sodium valproate, and the antidepressants amitriptyline, venlafaxine, and duloxetine.
The guidelines, developed in collaboration with the American Association of Neuromuscular and Electrodiagnostic Medicine and the American Academy of Physical Medicine and Rehabilitation, also provide direction on the use of nonpharmacologic treatments for painful neuropathy.

Comments

  1. Thank you for providing information regarding latest treatment for diabetic neuropathy.

    ReplyDelete
  2. Commonly used agents, including the recently approved duloxetine and pregabalin, are reviewed, and their effective dose ranges, titration schemes, contraindications, and recommended monitoring are discussed, so neuropathy equipment is must.

    ReplyDelete
  3. The diagnosis, prevention, management of painful diabetic neuropathy and diabetic neuropathic pain . This condition can be difficult to treat, which frustrates both providers and patients.

    ReplyDelete
  4. diabetic neuropathic pain is a common complication of diabetes and can affect many aspects of life and severely limit patients' daily functions.

    ReplyDelete

Post a Comment

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...

Fake drugs given to NHS patients still untraced

Only eight people out of several thousand who received counterfeit drugs from the NHS in an incident in 2007 have been identified. Of those eight, only three have been informed about the incident, a BBC investigation has learned. 72,000 packs of counterfeit drugs entered the UK supply chain in 2007 but 25,000 remain untraced. The regulator, the MHRA, has said it took swift action in 2007 and issued its "most serious recall notice". A new EU directive will further improve patient safety, it added. In the spring of 2007, the Medicines and Healthcare products Regulatory Agency (MHRA) issued an emergency recall of drugs which had been identified as counterfeit. Those recalled included batches of the prostate cancer drug Casodex; of a drug used to treat heart complaints called Plavix; and of Zyprexa, which is used to control the symptoms of schizophrenia. The MHRA successfully seized 40,000 packs before they were distributed to pharmacies but 25,000 reached chemists acros...